Clinical trials: Osteoporosis, Post-Menopausal
Post Menopausal Osteoporosis
Study of the Impact of Mother-of-pearl Nutritional Supplementation on the Prevention of Post-menopausal Osteoporosis
Post-menopausal osteoporosis and the resulting fractures are an important cause of disability and loss of independence. They also increase the risk of morbidity and mortality.
- Trial name
- NUTRANACRE (NCT05571514)
- Testing
- Mother-of-pearl, Calcium Carbonate
- Where
- 7 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Postmenopause, Osteoporosis
PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)
The objectives of the study are to describe the quality of life at the beginning of the Preotact® treatment and at the end of the observational period (Qualeffo-41 questionnaire) pain assessment at the beginning of the Preotact®…
- Trial name
- NCT00515593
- Testing
- Parathyroid hormone (PTH) (Preotact)
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- Nycomed
Postmenopausal Osteoporosis
Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults
This is a single-center, randomized, open label, single-dose, the original drug controlled, crossover design, two sequence, two periods, Phase Ⅰclinical study.
- Trial name
- NCT04747392
- Testing
- SAL001, FORSTEO
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Postmenopausal Osteoporosis
Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO
A 2-year, Multicenter, Open-label, Phase IIIb Extension Study to Assess Bone Mineral Density and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women with Postmenopausal Osteoporosis Who Sequentially Completed…
- Trial name
- NCT00577421
- Testing
- risedronate
- Where
- 5 sites in Australia, Italy and 3 more
- Volunteers
- 32 people
- Sponsor
- Warner Chilcott
Postmenopausal Osteoporosis
A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
The purpose of this study is to compare 2 formulations of romosozumab (AMG 785) on bone mineral density (BMD) in postmenopausal women with osteoporosis.
- Trial name
- NCT02016716
- Testing
- Romosozumab 90 mg/mL, Romosozumab 70 mg/mL
- Where
- 12 sites in United States, Czechia and 1 more
- Volunteers
- 294 people
- Sponsor
- Amgen
Osteoporosis
Efficacy of Cone Beam Computed Tomography in Diagnosing Osteoporosis
SUMMARY TITLE: "Efficacy of Cone Beam Computed Tomography derived radiomorphometric indices in screening of postmenopausal females for osteoporosis." RATIONALE: Osteoporosis is a disease of altered bone architecture affecting…
- Trial name
- NCT04365504
- Testing
- Dual energy X ray absorbtiometry
- Where
- India
- Volunteers
- 48 people
- Sponsor
- Postgraduate Institute of Dental Sciences Rohtak
Osteoporosis, Postmenopausal
Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Julina for postmenopausal osteoporosis.
- Trial name
- JULINA-CLIMA (NCT01386281)
- Testing
- E2 transdermal (Julina, BAY86-5435)
- Where
- Japan
- Volunteers
- 506 people
- Sponsor
- Bayer
Osteoporosis
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis
This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.
- Trial name
- NCT00089791
- Testing
- Denosumab
- Volunteers
- 7,808 people
- Sponsor
- Amgen
Osteoporosis, Postmenopausal, Osteoporosis, Steroid Induced
Adherence to Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication
This is a study aiming to investigate a possible correlation between the parameters affecting the physicians' therapeutic choice with the patients' overall adherence to osteoporosis treatment.
- Trial name
- IASIS (NCT02472782)
- Testing
- Teriparatide
- Where
- Greece
- Volunteers
- 851 people
- Sponsor
- 251 Hellenic Air Force & VA General Hospital
Postmenopausal Osteoporosis
Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis
The purpose of this study is to provide 24 months of standard of care data on participants previously enrolled in Study BA058-05-003 (NCT02653417).
- Trial name
- ACTIVExtend (NCT01657162)
- Testing
- Alendronate
- Where
- 25 sites in United States, Argentina and 8 more
- Volunteers
- 1,139 people
- Sponsor
- Radius Health, Inc.
Osteoporosis, Postmenopausal, Periodontitis
Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis
Symptoms of periodontal disease are tissue destruction and destruction of the alveolar bone which supports the tooth. Wnt way (wingless-type MMTV integration site family) plays a role in the regulation of bone homeostasis in…
- Trial name
- NCT04149405
- Testing
- Phase 1 periodontal therapy, Bisphosphonate therapy
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Ondokuz Mayıs University
Osteoporosis
Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass
This study will evaluate the efficacy of acetaminophen or fluvastatin in reducing the rate of occurrence and the severity of post dose symptoms that may occur during the 3 day period following a zoledronic acid infusion in post…
- Trial name
- NCT00489424
- Testing
- Acetaminophen, Fluvastatin
- Where
- United States
- Volunteers
- 793 people
- Sponsor
- Novartis Pharmaceuticals